Transplants for the Old But Not for the Young?—The Enigma of Adult ALL  by Sellar, Rob S. & Goldstone, Anthony H.
SECTION XII: ACUTE LEUKEMIAFrom the
tal, Lo
Financial d
Correspon
Depar
Eusto
goldst
 2011 Am
1083-8791
doi:10.101Transplants for the Old But Not for the Young?—The
Enigma of Adult ALL
Rob S. Sellar, Anthony H. GoldstoneThe outcome of treatment for adults with acute age 15. The improved survival in children treated
lymphoblastic leukaemia (ALL) falls disappointingly
short of the treatment outcomes for children. The latter
is a shining example of the success of combination che-
motherapy in curing malignancies, and results of recent
trials suggest that up to 90% of children may be cured
of their disease [1]. In contrast, although with modern
chemotherapy adult patients with ALL now have
a 90% chance of entering complete remission (CR),
most patients still relapse. Leukemia-free survival with
follow-up between 3 and 7 years is only 30% to 40%,
with survival inversely proportional to age [1,2].
These poorer outcomes for adults compared with
children almost certainly relates to multiple factors.
Adults have a higher incidence of poor prognostic
markers such as the Philadelphia chromosome and
lower incidence of favorable subtypes such as t(12;21)/
ETV6-RUNX1 and high hyperdiploidy. For example,
the Philadelphia chromosome is present in approxi-
mately 20% to 30% of adult ALL, but only 2% to
3% of childhood ALL [3,4]. Other factors, however,
remain unknown or unproven.
A large part of the debate in the treatment of adult
ALL centers on the best approach for adults who attain
first CR. In considering the way forward for the older
patient and whether it should involve increased use of
allogeneic transplants, or whether it should focus on
adopting more use of intensive pediatric protocols,
we must define the argument. First, who constitutes
an ‘‘adult’’ with ALL, and second, what differentiates
standard risk from high risk, because in many circum-
stances it is the higher risk patient who is put forward
for allogeneic transplant.
Fifteen to 20 years ago patients were treated with
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adopted for older teenagers and young adults. The ev-
idence and rationale for this will be discussed later, but
it has led to a redefiniton of ‘‘adults.’’ The current
UKALL 2003 trial has extended the upper age limit
of eligibility to a patient’s 25th birthday.
Risk has traditionally been defined by certain char-
acteristics of the patient at presentation or diagnosis
and before any treatment has been given at all. The
MRC UKALL XII/ECOG E2993 trial included pres-
ence of Philadelphia chromosome t(9;22), B-ALL with
presentingwhite cell count (WCC). 30109/dL, and
T-ALL withWCC.100 109/dL as being high risk.
Importantly, age .35 years was also considered high-
risk disease. Age is currently the single most important
prognostic factor and, although there is a continuum
with advancing age, age over 35 has been shown to be
a significant cutoff among adults, and has been used
in other prospective clinical trials [5]. A recent MRC/
ECOG publication has also highlighted other high
risk cytogenetic groups, which include t(4;11), t(8;14),
low hypodiploidy, near triploidy, and a complex
karyotype [3]. Interestingly, a report from SWOG-
9400 suggested that when the effect of cytogenetics
on overall survival (OS) was accounted for, age was
not a prognostic factor of significance [6]. However,
this was a study on the outcome of 200 patients, only
140 of which were evaluable for cytogenetics, and it
may be there is more to ALL with increasing age than
simply an increased frequency of high-risk cytogenetic
lesions.
Increasingly, risk can be redefined, or at least mod-
ified during treatment based on disease dynamics. In
addition to characteristics at presentation, some trials
have focussed on the rapidity of blast clearance and
the time taken to achieve CR. More recently formal
assessment of minimal residual disease (MRD), where
a suitable marker exists, have been used to try and
refine prognostic groups. The possible impact of
MRD monitoring on both decision to transplant and
type of transplant will be returned to later.
Numerous trials have been conducted over recent
years incorporating both autologous and allogeneic
stem cell transplantation (alloSCT) into the treatmentS71
S72 Biol Blood Marrow Transplant 17:S71-S75, 2011R. S. Sellar and A. H. Goldstonealgorithm. These trials, although varying in design,
have generally demonstrated that allogeneic transplant
is more effective than autologous transplant or chemo-
therapy in either high-risk patients or in older patients
treated, including standard-risk patients. The largest
of these studies UKALL XII/ECOG 2993 employed
a ‘‘biological randomization’’ on a donor versus no-
donor basis. The 443 patients with a donor, when com-
pared to the588patientswithout adonor,hada superior
event-free survival (EFS) of 50% versus 41% (P5 .009)
and OS of 53% versus 45% (P5 .01) [7]. A similar sta-
tistically significant benefit was seen in the no-donor
group, which was restricted to those whowere random-
ized to the chemotherapy armonly.Of importance, this
benefit was primarily seen in the standard-risk patients
OS, 62% for donor versus 52% for no donor (P5 .02).
In high-risk patients the increasedOS did not reach sta-
tistical significance, OS 40% for donor versus 36% for
no donor (P 5 .6). This lack of difference in outcome
between donor and no-donor patients in the higher
risk patients was related to a high nonrelapsedmortality
(NRM)of 36%at 2 years for thehigh-risk patients com-
pared to 20% at 2 years for the standard-risk patients.
Furthermore, this difference was largely related to
what happened in older patients. Among high-risk
patients, age over 35 was the only factor that could
be shown to be independently responsible for the
increased NRM [7].
An additional justification for considering alloSCT
infirstCR is the dismal outcomeof patientswho relapse
fromfirst CR. In theUKALLXII/ECOG2993 cohort,
5-yearOS in those relapsing fromfirstCRwas only 7%.
Hence, on a donor versus no-donor basis, many con-
sider allogeneic transplantation to be the treatment of
choice for eligible adults in first CR. At present, a group
of adults with ALL in whom the risk of relapse is less
than the risk of sibling allogeneic transplant cannot be
defined with certainty, although information from
MRD studies may identify such a cohort [2].SHOULD INTENSIVE CHEMOTHERAPY
REPLACE TRANSPLANTATION FOR
YOUNGER ADULTS WITH ALL?
The issue of the optimal management for young
adults with ALL is of considerable interest with reports
by pediatric groups of an apparently superior outcome
for adolescents treated on pediatric regimens. This
information comes from comparative data between
outcomes of patients treated on pediatric versus adult
protocols, for example, CCG versus CALGB [8],
LALA-94 versusFRALLE93 [9], andMRCALL97ver-
sus UKALL XII [10]. Based on theses comparisons
several groups arenowusingpediatric regimens in young
adults up to the endof the thirddecade. Indeed, a phase II
study from the Dana Farber, is investigating the safetyand efficacy of a pediatric regimen including pegylated
L-asparaginase in those aged 18 to 50 (Study 06-254).
Huget et al. have recently published a phase II trial of
225 adult patients aged 15 to 60 (median age31) suggest-
ing improved outcome in adults up to the age of 45
treated with pediatric protocols [11]. However, it is im-
portant to emphasize that these protocols have been
adopted for use in young adults rather than assessed for
use in young adults using prospective trials. Published
comparisons are retrospective and commonly contrast
cohorts treated in pediatric units versus adult units.
Furthermore, in many of these studies the age pro-
files of the teenagers and young adult patients in both
groups are not entirely comparable. If one considers
the UK study comparing MRC ALL 97 with UKALL
XII, there are considerable difference between the 2
groups [10]. In the pediatric group there were 47 pa-
tients aged 15, 12 patients aged 16, and 2 aged 17 years.
In the ‘‘adult’’ group there were 11 patients aged 15, 22
patients aged 16 years, and 34 patients aged 17 years.
The P-value for this comparison is \.0001. In fact,
in a multivariate analysis of this study, age and Phila-
delphia chromosome status were significant factors
affecting outcome, whereas trial chemotherapy and
treatment approach were not.
Moreover, if one examines the outcome of the
Ribera study of standard-risk ALL patients aged 15
to 30 and looks at those aged 19 to 30 in particular,
OS does not differ from the 15 to 35 age group in
UKALL XII/ECOG study [12]. In the PETHEMA
group, OS in the 19 to 30 age group (n 5 46) was
63%, whereas in the UKALL XII/ECOG 2993 pa-
tients aged 15 to 35 OS (n 5 323) was 62%.
So, although comparative data has convincedmany
investigators that at least up until the age of 25 years
teenagers and young adults are best treated using in-
tensive, pediatric style, chemotherapy regimens, the
case is far from proven. In fact, theMRC/ECOG study
showed that in each and every age subgroup up to 40,
including those aged\20, there was an OS advantage
to having a donor. There is insufficient evidence to say
that an allogeneic transplant in first CR should be
abandoned in this group of patients, particularly for
those with high-risk disease. Despite this, the speed
and enthusiasm with which pediatric style protocol
have been adopted for young adults suggests that, for
the foreseeable future, we will see fewer transplants
in ALL within this age group.THE USE OF REDUCED-INTENSITY
CONDITIONING (RIC) AND UNRELATED
DONORS IN TRANSPLANTATION FOR
ADULTALL
Two meta-analyses conducted on abstracted data
have evaluated the roleof alloHSCTinadultALLinfirst
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advantage in allogeneic transplantation. Yanada et al.
analyzed 7 published studies and reported a significant
advantage for sibling alloHSCT in high-risk patients.
However, no benefit was found in those patients who
were not high risk.
In contrast, the UKALL XII/ECOG 2993 trial,
the largest prospective study to date, reported a survival
advantage in standard-risk patients but no such benefit
in OS for those patients deemed high risk. Despite the
reduced relapsed risk in high-risk patients (63% no
donor versus 37% donor, P\.00005), the transplant-
related mortality of 36% at 2 years for high-risk pa-
tients abrogated the survival benefits of reduction in
relapse. Because 1 of the criteria for high risk is age
.35 years, and transplant-realted mortality (TRM)
increases with advancing age, it is probable that ad-
vancing age in the high-risk group explains this in-
creased TRM. Subgroup numbers do not, however,
allow statistical proof of this theory, and it is unclear
whether high-risk patients younger than 35 will also
fail to show survival advantage.
In these studies, the age of tipping point at which
TRM exceeds reduction in relapse risk may be as low
as 35 to 40 years. A more recent meta-analysis of adult
patients aged.15 years with ALL in first CR, which in-
cluded the UKALL XII/ECOG 2993 data, revealed
survival advantage for standard-risk patients and a non-
significant survival advantage for high-risk patients [15].
Prospective trials in ALL have used full-intensity,
myeloablative, allogeneic regimens that include total-
body irradiation (TBI). However, RIC regimens may
allow us to employ the therapeutic benefit of a graft-
versus-leukemia (GVL) effect with less transplant-
related toxicity and thus offer transplantation to older
patients more safely.
Attempts to harness the GVL effect in elderly pa-
tients using RIC has already been investigated in acute
myeloid leukaemia (AML). Indeed, RIC allogeneic he-
matopoietic stem cell transplant (HSCT) from
a matched sibling is included as a treatment option in-
the current prospective trial for elderly AML: AML16.
Most recently a series of 247 patients with AML with
median age of 60 underwent allogeneic HSCT from
both related and unrelated donors [16]. The estimated
OS at 5 years was 33%. The estimated 5-year relapse/
progression and NRM were 42% and 26%, respec-
tively. Thus, RIC allogeneic transplants in older adults
appear to be an efficacious treatment option, at least in
AML. Of interest, and potential importance, is that
patients with HLA-matched related or unrelated do-
nors had similar survivals.
Despite clear evidence of a GVL effect in ALL
[17], investigation of RIC in ALL has lagged behind
studies in other diseases. However, several reports
have now been published on RIC in ALL, althoughresults have been difficult to fully evaluate because of
regimen variability and small numbers.
Recent data from the City of Hope National Medi-
calCentre inCalifornia reported on 21patients, primar-
ily with high-risk disease, who received Fludarabine and
Melphalan conditioning followed by matched related
(33%) or unrelated (67%) transplant [18]. Only 10
patients were being transplanted in first CR. With
a 17-month follow-up, 1-year cumulative probability
of OS was 77%, disease-free survival (DFS) was 81%,
and relapse was 8%. The 100-day NRM was 10%.
Other groups have also presented their experiences
of RIC in adults with ALL. The European Group for
Blood andMarrow Transplantation (EBMT) reported
the outcome of 97 adults with ALL who received RIC
alloHSCT [19]. Although only 29% of patients were
transplanted in first CR, they reported a 2-year OS
of 31% with an NRM of 18%. For those transplanted
in first CR, a 2-year OS of 52% was reported.
Marks et al. [20] examined the efficacy of RIC in
Philadelphia negative ALL and compared outcomes
of 93 adult patients receiving RIC alloHSCT, with
1428 receiving full-intensity allografts using sibling
and unrelated donors in first CR or second CR.
Although transplanted at 57 centers using various con-
ditioning regimens, it is intriguing that the RIC cohort
had similar OS to the full-intensity cohort at 3 years
(38% versus 43%, P5 .39) despite a substantially older
median age (45 versus 28 years, P\.01).
A further report from the EBMT retrospectively
compares outcome of 576 adult ALL patients aged 45
and over who received RIC (n5 127) or myeloablative
conditioning (MAC) (n 5 449) followed by allogeneic
stem cell transplant from an HLA-identical sibling in
CR [21]. With a median follow-up of 16 months,
NRM was significantly higher in the MAC cohort,
with relapse significantly higher in the RIC cohort. In
multivariate analysis, the conditioning regimen was
not significantly associatedwith leukemia-free survival.
This does suggest that RIC is feasible in adult
ALL, and that it merits examination in prospective tri-
als. In addition to improving safety of transplantation
in the older age groups, it may extend the option of
an allogeneic transplant to groups previously excluded
from transplant because of comorbidity.
In addition, the use of unrelated donors may ex-
tend the transplant option to those previously excluded
on the basis of not having a suitable sibling donor. Pre-
viously, the perceived risk of matched unrelated donor
(MUD) transplants meant that they were only deemed
appropriate for those with the very highest risk disease,
that is, those patients with a Philadelphia chromo-
some. The study by Marks [20] showed that partially
matched and mismatched unrelated donors had higher
TRM on multivariate analysis in both RIC and
MAC transplants. Increasingly, however, data suggests
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a MUD when compared with sibling transplants.
The feasibility of a MUD transplant in first CR is sup-
ported by an observational study from the CI-BMTR
which reported 5-year survival on mostly high-risk pa-
tients [22]. The 5-year TRM, relapse, and OS were
42%, 20%, and 39%, respectively. TRM was signifi-
cantly higher with HLA mismatched donors. Given
that almost 40% of adults with ALL in CR1 survive
5 years after unrelated transplantation, it would appear
to be reasonable to consider a MUD for high-risk pa-
tients in CR1, especially if a closely matched donor is
identified. In the UKALL 14 trial, other high-risk sub-
groups, in addition to Philadelphia chromosome posi-
tive patients, will be considered for MUD allograft.
Whether it is also appropriate to extend the option
ofMUD allograft to standard-risk patients is less clear.
However, as stated, there are an increasing number of
reports showing comparable outcomes for sibling
transplants when compared with well-matched unre-
lated transplants. Kiehl et al. [23] reported their
findings of 264 adults receiving allogeneic transplants
for adult ALL. For those receiving transplants in first
CR they found no difference between MUD and
matched sibling donors. The exact role of MUD allo-
graft in standard-risk adult ALL remains to be evalu-
ated. However, on the evidence presented, it seems
reasonable and indeed important that such a question
be addressed in prospective trials.CAN MRD STUDIES GUIDE
TRANSPLANTATION DECISIONS?
The success of the RIC approach is likely to be
influenced by disease burden at the time of transplant.
Historically, clinical trials have defined the success of
induction chemotherapy on the basis of morphology.
However, both molecular and immunophenotypic
methods can be used to reliably detect the presence
of 1 blast in 10,000 normal cells. It is true now that
the vast majority of patients with adult ALL can have
targets identified from which measurement of MRD
can be used at different times in the treatment course
and potentially identify groups at risk. It may be that
MRD studies can be used both to predict at risk groups
who might benefit from transplant, and in addition,
provide guidance as to the most suitable conditioning
regimen. Of course, the relevance of MRD at any time
point is dependent on the specifics of therapy and
possibly cannot be extrapolated from 1 protocol to
another.
In a significant study published in 2009 by Bassan
et al. [24] from the North Italian Study Group of
223 patients, study probes were obtained in 88%
with a single marker in 61%. A sensitivity level of
1024 or higher was found in 94.2% of patients andrisk based data is available on 78.9% of patients who
completed the first stage of treatment. In patients
with sensitive probes, bone marrow relapse occurred
in only 18.5% of MRD-negative patients.
In an earlier study, Bruggeman [25] reported for
the German study group GMALL a series of 196
standard-risk patients who had theirMRD status mon-
itored prospectively. In an apparently homogenous
group at week 16 of therapy they were able to identify
subsets with strikingly disparate outcomes. Those pa-
tients (23%) who had MRD detectable until week 16
and beyond had a 3-year relapse rate of 94%. In con-
trast, in the 10% of patients who had a rapid decline
to undetectable MRD levels when measured at days
11 and 24, no relapses occurred.
Thus, with MRD analysis, 90% remain transplant
candidates as patients with standard-risk adult ALL.
Furthermore, those with highest risk disease might
reasonably be considered for MUD allograft. There-
fore, 33% of ‘‘standard-risk’’ patients can be identified
as being at the extremes of risk, either good (10%) or
poor (23%), and potentially have their treatment rad-
ically altered as a result. It remains to be seen whether
future work will show that patients who areMRD neg-
ative at a later stage than day 24 go on with a reduced
relapse rate if they are not subjected to allogeneic
transplant.
More recently, Stow et al. [26] attempted to refine
MRD risk still further in a pediatric ALL population.
Using polymerase chain reaction (PCR) amplification
of antigen-receptor genes they were able to detect 1
leukemic cell per 100,000 normal mononuclear cells
(.001%). They examined 455 patients and compared
2 cohorts based on MRD levels at day 46 of therapy.
Those patients withMRD\.001% had 5 year relapsed
risk of 5% compared with 12.7% for those with MRD
levels of .001% to \.01% (P \.047). Interestingly,
within this group, none of the presenting features
tested was prognostically informative. Although this
study was in a pediatric population, the principle is
an important one. As the limits of disease detection
improve, MRD may prove more important than any
defined presenting characteristics and thus define
transplant recipients.CONCLUSION
TRM for patients with ALL treated with MAC
transplants increases with age. However, with chemo-
therapy alone there is a very considerable drop off in
OS with each decade over the age of 50, and the me-
dian age of adults with ALL is close to 60.
The potential availability of suitable sibling and
unrelated donors, as well as suitable conditioning reg-
imens, not only for patients under 40 years but also for
the patient between 40 and 60 years, will undoubtedly
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opens the possibility of improved survival to patients
over 40, regardless of how many younger adults ulti-
mately benefit from more intensive chemotherapy
rather than transplantation in first CR.
DiseaseburdenmeasuredbyMRDmay in the future
be themost prognostically significant way of identifying
the highest risk patients and those who might benefit
from transplant. Depth of response, as measured by
MRD, may also allow more judicious use of RIC regi-
mens in place of MAC regimens and thus limit the
toxicity of transplantation in all age groups.ACKNOWLEDGMENTS
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